No price history available.
Key financial summary
Financials in NOK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | NOKm | 229 | 329 | 367 | 410 | 425 | 494 | N/A | N/A |
| Operating profit | NOKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | NOKm | -9 | -89 | -132 | 104 | -67 | 7 | N/A | N/A |
| EPS reported | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | NOKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | NOKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | NOKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | NOK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in NOK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Founded in 1999 and headquartered in Oslo, Norway, Omda AS delivers specialized software solutions to the healthcare and emergency response sectors across Norway, Sweden, Denmark, Finland, and internationally. Its software suite encompasses sophisticated laboratory information management systems, including Omda ProSang for managing blood, cell, and tissue data, as well as dedicated medical medication software like Omda Cytodose, designed for oncology treatment management. The company also offers a broad array of connected healthcare solutions. These include Omda Cardio for ECG and diagnostic archiving, mobile clinical imaging through Omda CIMA, web-based medical imaging tools such as Omda Media, and comprehensive image management and workflow solutions like Omda Medimaker and Omda Picsara. The connected healthcare portfolio also extends to Omda Arcidis, an integrated teleradiology system; Omda Helsemail, enabling secure patient data transfer; Omda Plutus for audit and workflow monitoring; Omda S7, a secure e-care communication platform; and Omda XDS for efficient patient data storage and management. Within the advanced assisted reproductive technology (ART) and maternity sectors, Omda delivers specialized data solutions. These include Omda Fertsoft for ART clinics, Omda iPana Hospital for digital maternity management, Omda iPana Maternity, a cloud-based platform supporting women's maternal care, and Omda Partus for comprehensive maternity sector data management. Furthermore, its health analytics offerings, such as Omda Compos for medical data management and Omda MedSciNet, facilitate the collection, analysis, and overall governance of medical data. Moreover, Omda provides crucial support to emergency organizations with robust solutions. Omda Optima enables digital simulations for testing resource distribution and operational strategies. This is complemented by Omda CoordCom, an integrated emergency response platform; Omda AMIS, a digital system for processing emergency calls and coordinating medical responses; and Omda Paratus, a dedicated emergency response system. Originally established as CSAM Health Group AS, the company adopted its current name, Omda AS, in September 2023.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Founded in 1999 and headquartered in Oslo, Norway, Omda AS delivers specialized software solutions to the healthcare and emergency response sectors across Norway, Sweden, Denmark, Finland, and internationally. Its software suite encompasses sophisticated laboratory information management systems, including Omda ProSang for managing blood, cell, and tissue data, as well as dedicated medical medication software like Omda Cytodose, designed for oncology treatment management. The company also offers a broad array of connected healthcare solutions. These include Omda Cardio for ECG and diagnostic archiving, mobile clinical imaging through Omda CIMA, web-based medical imaging tools such as Omda Media, and comprehensive image management and workflow solutions like Omda Medimaker and Omda Picsara. The connected healthcare portfolio also extends to Omda Arcidis, an integrated teleradiology system; Omda Helsemail, enabling secure patient data transfer; Omda Plutus for audit and workflow monitoring; Omda S7, a secure e-care communication platform; and Omda XDS for efficient patient data storage and management. Within the advanced assisted reproductive technology (ART) and maternity sectors, Omda delivers specialized data solutions. These include Omda Fertsoft for ART clinics, Omda iPana Hospital for digital maternity management, Omda iPana Maternity, a cloud-based platform supporting women's maternal care, and Omda Partus for comprehensive maternity sector data management. Furthermore, its health analytics offerings, such as Omda Compos for medical data management and Omda MedSciNet, facilitate the collection, analysis, and overall governance of medical data. Moreover, Omda provides crucial support to emergency organizations with robust solutions. Omda Optima enables digital simulations for testing resource distribution and operational strategies. This is complemented by Omda CoordCom, an integrated emergency response platform; Omda AMIS, a digital system for processing emergency calls and coordinating medical responses; and Omda Paratus, a dedicated emergency response system. Originally established as CSAM Health Group AS, the company adopted its current name, Omda AS, in September 2023.